An open-label, phase 2, long-term safety study of inhaled insulin: an up to four-year extension of therapy in subjects with type 1 or type 2 diabetes mellitus participating in extension protocols 217-102, 103, or 104.

Trial Profile

An open-label, phase 2, long-term safety study of inhaled insulin: an up to four-year extension of therapy in subjects with type 1 or type 2 diabetes mellitus participating in extension protocols 217-102, 103, or 104.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2010

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Nov 2009 Planned number of patients changed from 70 to 173 as reported by ClinicalTrials.gov.
    • 19 Dec 2007 Status changed from in progress to discontinued. Clinicaltrials.gov states "Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons."
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top